** Brokerage Jefferies says quarterly sales growth of Spravato, Johnson & Johnson's JNJ.N nasal spray for treatment-resistant depression, bodes well for psychedelic treatments

** JNJ reports Q1 sales of $320 million for Spravato, up 41.9% from a year earlier

** JNJ's commitment to building out infrastructure by working with hospitals or physicians and marketing the drug should only help facilitate adoption of future psychedelics, says Jefferies

** Brokerage says existing players in this space such as Atai Life Sciences 9VC.DE could "eventually leverage the global infrastructure built by JNJ"

** Atai's depression drug BPL-003 is currently in mid-stage development

** U.S.-listed shares of Atai ATAI.O up 3.3%

** Shares of Compass Pathways CMPS.O, which also has a psychedelic depression treatment in development, climbs 1.7%

** Including session's move, ATAI up 5.3%, CMPS down 18.8% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))